KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Liabilities: 2009-2024

Historic Total Liabilities for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $243.1 million.

  • Nektar Therapeutics' Total Liabilities fell 16.53% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.3 million, marking a year-over-year decrease of 16.53%. This contributed to the annual value of $243.1 million for FY2024, which is 8.96% down from last year.
  • As of FY2024, Nektar Therapeutics' Total Liabilities stood at $243.1 million, which was down 8.96% from $267.0 million recorded in FY2023.
  • Over the past 5 years, Nektar Therapeutics' Total Liabilities peaked at $461.5 million during FY2020, and registered a low of $243.1 million during FY2024.
  • For the 3-year period, Nektar Therapeutics' Total Liabilities averaged around $284.7 million, with its median value being $267.0 million (2023).
  • Data for Nektar Therapeutics' Total Liabilities shows a maximum YoY declined of 22.36% (in 2023) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Total Liabilities (Yearly) stood at $461.5 million in 2020, then decreased by 5.16% to $437.7 million in 2021, then dropped by 21.41% to $344.0 million in 2022, then fell by 22.36% to $267.0 million in 2023, then decreased by 8.96% to $243.1 million in 2024.